Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

In the Sean 'Diddy' Combs trial, an ex-girl­friend testifies about abuse and control BY Associated Press Manhattan UPDATED 3:45 PM ET Jun. 05, 2025 ...